Preliminary results of a phase II neoadjuvant trial with gemcitabine/oxaliplatin and cetuximab followed by surgery or concurrent intensity modulated radiation therapy (IMRT) with capecitabine for patients with borderline resectable and unresectable nonmetastatic pancreatic cancer

被引：0
|
作者：
Chaudhary, U. B. [1 ]
Gudena, V. [1 ]
Milling, D. L. [1 ]
O'Brien, P. [1 ]
Montero, A. J. [1 ]
Brashears, J. [1 ]
Marshall, D. [1 ]
Hoffman, B. [1 ]
Garrett-Mayer, E. [1 ]
Esnaola, N. [1 ]
机构：
[1] Med Univ S Carolina, Charleston, SC 29425 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15506
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I trial of full-dose gemcitabine, oxaliplatin, and radiation therapy for unresectable pancreatic cancer: Preliminary analysis
    Feng, F. Y.
    Griffith, K. A.
    Murphy, J. D.
    Francis, I. R.
    Desai, S. P.
    Lawrence, T. S.
    Zalupski, M. M.
    Ben-Josef, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S308 - S309
  • [22] Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
    Badiyan, Shahed N.
    Olsen, Jeffrey R.
    Lee, Andrew Y.
    Yano, Motoyo
    Menias, Christine O.
    Khwaja, Shariq
    Wang-Gillam, Andrea
    Strasberg, Steven M.
    Hawkins, William G.
    Linehan, David C.
    Myerson, Robert J.
    Parikh, Parag J.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (01): : 1 - 7
  • [23] Quality of Life in a Prospective, Multicenter Phase 2 Trial of Neoadjuvant Full-Dose Gemcitabine, Oxaliplatin, and Radiation in Patients With Resectable or Borderline Resectable Pancreatic Adenocarcinoma
    Serrano, Pablo E.
    Herman, Joseph M.
    Griffith, Kent A.
    Zalupski, Mark M.
    Kim, Edward J.
    Bekaii-Saab, Tanios S.
    Ben-Josef, Edgar
    Dawson, Laura A.
    Ringash, Jolie
    Wei, Alice C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 (02): : 270 - 277
  • [24] Phase I study of veliparib with gemcitabine and radiation therapy in patients with borderline resectable and locally advanced unresectable pancreatic cancer.
    Tuli, Richard
    Nissen, Nicholas N.
    Annamalai, Alagappan
    Hoffman, David M. J.
    Bryant, Miranda
    Tighiouart, Mourad
    Rogatko, Andre
    Rokhsar, Sepehr
    Scher, Kevin S.
    Jamil, Laith
    Lo, Simon
    Hendifar, Andrew Eugene
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [25] Prognostic Value of CA 19-9 in a Phase I/II Trial of Dose Escalated Intensity Modulated Radiation Therapy (IMRT) With Concurrent Full-dose Gemcitabine (G) in Unresectable Pancreatic Cancer
    Vainshtein, J. M.
    Schipper, M.
    Zalupski, M.
    Lawrence, T. S.
    Abrams, R.
    Francis, I. R.
    Leslie, W.
    Ben-Josef, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S146 - S147
  • [26] Preliminary Results of Ongoing Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) Combined With Capecitabine for High-risk Gastric Cancer Patients
    Ren, H.
    Jin, J.
    Li, Y.
    Wang, X.
    Li, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S315 - S315
  • [27] GEMCITABINE, OXALIPLATIN AND CAPECITABINE (GEMOXEL) FOR PATIENTS WITH ADVANCED PANCREATIC ADENOCARCINOMA (APC). PRELIMINARY RESULTS OF AN ONGOING PHASE I/II TRIAL
    Hess, V.
    Pestalozzi, B.
    Ludwig, C.
    Winterhalder, R.
    Lohri, A.
    Jost, L.
    Widmer, L.
    Lee, L.
    Stillhart, P.
    Herrmann, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 181 - 181
  • [28] Efficacy and safety of neoadjuvant therapy with stereotactic body radiation therapy followed by nab-paclitaxel/gemcitabine plus camrelizumab for resectable, borderline resectable and locally advanced pancreatic cancer: Preliminary results.
    Xue, Jun
    Hu, Yue
    Gou, ShanMiao
    Yin, Tao
    Li, Xin
    Wang, Jing
    Liu, Hongli
    Yang, Ming
    Ma, Hong
    Hu, Jianli
    Lin, Zhenyu
    Li, Pindong
    Wu, Heshui
    Zhang, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16227 - E16227
  • [29] A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement
    Yuichi Nagakawa
    Yuichi Hosokawa
    Hidetsugu Nakayama
    Yatsuka Sahara
    Chie Takishita
    Tetsushi Nakajima
    Yousuke Hijikata
    Kazuhiko Kasuya
    Kenji Katsumata
    Koichi Tokuuye
    Akihiko Tsuchida
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 951 - 957
  • [30] A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement
    Nagakawa, Yuichi
    Hosokawa, Yuichi
    Nakayama, Hidetsugu
    Sahara, Yatsuka
    Takishita, Chie
    Nakajima, Tetsushi
    Hijikata, Yousuke
    Kasuya, Kazuhiko
    Katsumata, Kenji
    Tokuuye, Koichi
    Tsuchida, Akihiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (05) : 951 - 957
12345